Skip to content

Preoperative Laboratory Parameters and Scorings Systems on Postoperative Pulmonary Complications in Thoracic Surgery

Evaluation of the Effects of Preoperative Neutrophil/Lymphocyte Ratio, Albumin Level, and Various Risk Scorings on Postoperative Pulmonary Complications in Thoracic Surgery. Prospective Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04995939
Enrollment
130
Registered
2021-08-09
Start date
2021-03-15
Completion date
2021-11-15
Last updated
2022-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative/Postoperative Complications

Brief summary

Postoperative pulmonary complications (PPC) emerge as a major risk that determines the morbidity and mortality of patients after surgery. PPCs affect the length of hospital stay and increase health costs. Because of this reason, it is important to predict PPCs before surgery. There are many studies on scoring systems that can be effective in predicting PPCs. The most frequently used ones are the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) risk index, the Nutritional Risk Score (NRS), and the American Society of Anesthesiologist (ASA) score. ARISCAT risk index is mostly evaluated in operations performed other than thoracic surgery. Since the thoracic wall, mediastinum or lungs are directly intervened in thoracic surgery operations, the expected PPCs in these patients may be different from those expected in other surgical groups. Therefore, the ARISCAT risk index may be insufficient to evaluate PPCs in thoracic surgery.

Interventions

PROCEDURELaboratory parameters and Scoring systems

Neutrophil/ Lymphocite ratio, albumin level and scoring systems has been evaluated.

Sponsors

Atatürk Chest Diseases and Chest Surgery Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

* Patients who will undergo elective thoracotomy or video assisted thoracic surgery with general anesthesia * BMI \< 35 kg/m2 * Age 18 - 75 years old * Expected operative time more than 60 minutes

Exclusion criteria

* History of lung surgery * Advanced lung-heart disease * Having a previous COVID-19 pneumonia

Design outcomes

Primary

MeasureTime frameDescription
Distribution of patients who developed one or more postoperative pulmonary complications according to preoperative neutrophil/lymphocyte ratio, albumin value, ARISCAT risk index, nutritional risk score, and ASA physical status.Time to preoperative visit and through study completion, an average of three months.1. Effectiveness of the ARISCAT risk scoring index \[ Time Frame: postoperative first 30 days \] to investigate the effectiveness of the ARISCAT risk scoring index in predicting the development of PPC in patients undergoing thoracic surgery. 2. Correlation between ASA physical status (1-3) and PPC \[ Time Frame: postoperative first 30 days \] 3. Correlation between NRS ( nutritional risk score) score (0-3) and PPC \[ Time Frame: postoperative first 30 days \] 4. Correlation between preoperative albumin values (gram / dl) and PPC \[ Time Frame: postoperative first 30 days \] 5. Correlation between preoperative neutrophil/lymphocyte ratio and PPC \[ Time Frame: postoperative first 30 days \]

Secondary

MeasureTime frameDescription
Distribution of patients who developed one or more postoperative pulmonary complications according to age, gender, BMI and preoperative SpO2 level.Time to preoperative visit and up to 30 days.1. Correlation between age (years) and PPC \[ Time Frame: postoperative first 30 days 2. Correlation between gender(male or female) and PPC \[ Time Frame: postoperative first 30 days \] 3. Correlation between BMI (kg/m\^2) and PPC \[ Time Frame: postoperative first 30 days \] 4. Correlation between Preoperative Sp02(\>96%, 91%-95%, \<90%) and PPC \[ Time Frame: postoperative first 30 days \]

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026